Amylin vs Amycretin
Co-secreted with insulin; the satiety and gastric-emptying partner. GLP-1 and amylin agonism combined in a single molecule, not a two-drug combination. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Amylin IAPP | Amycretin | |
|---|---|---|
| Also known as | — | — |
| Type | Endogenous | Analog |
| Evidence | Established | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Islet amyloid polypeptide (37 aa) | Unimolecular GLP-1 + amylin receptor agonist (peptide) |
| Receptor | Amylin receptors (calcitonin receptor + RAMP complexes) | GLP-1 receptor + amylin receptors |
| Molecular weight | ~3,903.3 Da | ≈7,900 Da |
| Half-life | ~days (weekly SC dosing) | |
| Based on | Native hormone | Amylin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Amylin and Amycretin?
- Amylin is an endogenous hormone; Amycretin is an engineered analog based on Amylin. Amylin signals at Amylin receptors (calcitonin receptor + RAMP complexes); Amycretin signals at GLP-1 receptor + amylin receptors.
- How do the half-lives of IAPP and Amycretin compare?
- The reported circulating half-life of Amylin is ~13 min (native); Amycretin is ~days (weekly SC dosing). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Amycretin vs Amylin. Or open the interactive comparison tool to add more molecules.